Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
Günther, S.; Reinke, P. Y. A.; Oberthuer, D.; Yefanov, O.; Ginn, H.; Meier, S.; Lane, T. J.; Lorenzen, K.; Gelisio, L.; Brehm, W.; Dunkel, I.; Domaracky, M.; Saouane, S.; Lieske, J.; Ehrt, C.; Koua, F.; Tolstikova, A.; White, T. A.; Groessler, M.; Fleckenstein, H.; Trost, F.; Galchenkova, M.; Gevorkov, Y.; Li, C.; Awel, S.; Peck, A.; Xavier, P. L.; Barthelmess, M.; Schlünzen, F.; Werner, N.; Andaleeb, H.; Ullah, N.; Falke, S.; Franca, B. A.; Schwinzer, M.; Brognaro, H.; Seychell, B.; Gieseler, H.; Melo, D.; Zaitsev-Doyle, J. J.; Norton-Baker, B.; Knoska, J.; Esperanza, G.; Mashhour, A. R.; G
Show abstract
Here we present the crystal structure of SARS-CoV-2 main protease (Mpro) covalently bound to 2-methyl-1-tetralone. This complex was obtained by co-crystallization of Mpro with HEAT (2-(((4-hydroxyphenethyl)amino)methyl)-3,4-dihydronaphthalen-1(2H)-one) in the framework of a large X-ray crystallographic screening project of Mpro against a drug repurposing library, consisting of 5632 approved drugs or compounds in clinical phase trials. Further investigations showed that HEAT is cleaved by Mpro in an E1cB-like reaction mechanism into 2-methylene-1-tetralone and tyramine. The catalytic Cys145 subsequently binds covalently in a Michael addition to the methylene carbon atom of 2-methylene-1-tetralone. According to this postulated model HEAT is acting in a pro-drug-like fashion. It is metabolized by Mpro, followed by covalent binding of one metabolite to the active site. The structure of the covalent adduct elucidated in this study opens up a new path for developing non-peptidic inhibitors.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex 95%
- Integrative x-ray structure and molecular modeling for the rationalization of procaspase-8 inhibitor potency and selectivity 94%
- Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir 93%
Similar papers in this journal
- Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine 95%
- Targeting the Protein-Protein Interaction Between the CDC37 Co-Chaperone and Client Kinases by an Allosteric RAF Dimer Breaker 95%
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 95%
Similar papers in this journal
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 95%
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 95%
- Bepridil is Potent Against SARS-CoV-2 In Vitro 94%
Similar papers in this journal
- Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region 92%
- Discovery of 5,5'-methylenedi-2,3-cresotic acid as a potent inhibitor of the HMGB1/CXCL12 heterocomplex using Virtual Screening and NMR validation 92%
- Necator americanus Ancylostoma secreted protein-2 (Na-ASP-2) selectively binds an ascaroside (ascr#3) 91%
Similar papers in this journal
- Oligomerization of the Human Adenosine A2A Receptor Is Driven by the Intrinsically Disordered C-Terminus 93%
- Structural basis for the hyperthermostability of an archaeal glutaminase induced by post-translational succinimide formation 93%
- Structural and dynamic characterization of the C-terminal tail of ErbB2: disordered but not random 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.